220 related articles for article (PubMed ID: 25492170)
1. Gemcitabine loaded biodegradable PLGA nanospheres for in vitro pancreatic cancer therapy.
Jaidev LR; Krishnan UM; Sethuraman S
Mater Sci Eng C Mater Biol Appl; 2015 Feb; 47():40-7. PubMed ID: 25492170
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells.
Papa AL; Basu S; Sengupta P; Banerjee D; Sengupta S; Harfouche R
BMC Cancer; 2012 Sep; 12():419. PubMed ID: 22998550
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.
Allison Logan S; Brissenden AJ; Szewczuk MR; Neufeld RJ
Drug Des Devel Ther; 2017; 11():2239-2250. PubMed ID: 28814832
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate.
Khare V; Kour S; Alam N; Dubey RD; Saneja A; Koul M; Gupta AP; Singh D; Singh SK; Saxena AK; Gupta PN
Int J Pharm; 2014 Aug; 470(1-2):51-62. PubMed ID: 24810239
[TBL] [Abstract][Full Text] [Related]
5. Multi-functional nanoparticles as theranostic agents for the treatment & imaging of pancreatic cancer.
Jaidev LR; Chellappan DR; Bhavsar DV; Ranganathan R; Sivanantham B; Subramanian A; Sharma U; Jagannathan NR; Krishnan UM; Sethuraman S
Acta Biomater; 2017 Feb; 49():422-433. PubMed ID: 27890622
[TBL] [Abstract][Full Text] [Related]
6. Biocompatible gemcitabine-based nanomedicine engineered by Flow Focusing for efficient antitumor activity.
Martín-Banderas L; Sáez-Fernández E; Holgado MÁ; Durán-Lobato MM; Prados JC; Melguizo C; Arias JL
Int J Pharm; 2013 Feb; 443(1-2):103-9. PubMed ID: 23299085
[TBL] [Abstract][Full Text] [Related]
7. EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer.
Aggarwal S; Yadav S; Gupta S
J Biomed Nanotechnol; 2011 Feb; 7(1):137-8. PubMed ID: 21485840
[TBL] [Abstract][Full Text] [Related]
8. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects.
Tahara K; Yamamoto H; Hirashima N; Kawashima Y
Eur J Pharm Biopharm; 2010 Mar; 74(3):421-6. PubMed ID: 20034563
[TBL] [Abstract][Full Text] [Related]
9. Enhanced bioavailability and intestinal uptake of Gemcitabine HCl loaded PLGA nanoparticles after oral delivery.
Joshi G; Kumar A; Sawant K
Eur J Pharm Sci; 2014 Aug; 60():80-9. PubMed ID: 24810394
[TBL] [Abstract][Full Text] [Related]
10. BSA-PLGA-based core-shell nanoparticles as carrier system for water-soluble drugs.
Chitkara D; Kumar N
Pharm Res; 2013 Sep; 30(9):2396-409. PubMed ID: 23756758
[TBL] [Abstract][Full Text] [Related]
11. Poly(L-lactide-co-glycolide) nanospheres conjugated with a nuclear localization signal for delivery of plasmid DNA.
Jeon O; Lim HW; Lee M; Song SJ; Kim BS
J Drug Target; 2007 Apr; 15(3):190-8. PubMed ID: 17454356
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine hydrochloride-loaded liposomes and nanoparticles: comparison of encapsulation efficiency, drug release, particle size, and cytotoxicity.
Yalcin TE; Ilbasmis-Tamer S; Ibisoglu B; Özdemir A; Ark M; Takka S
Pharm Dev Technol; 2018 Jan; 23(1):76-86. PubMed ID: 28724327
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs) using central composite design.
Yalcin TE; Ilbasmis-Tamer S; Takka S
Int J Pharm; 2018 Sep; 548(1):255-262. PubMed ID: 29969712
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a stability indicating isocratic HPLC method for gemcitabine with application to drug release from poly lactic-co-glycolic acid nanoparticles and enzymatic degradation studies.
Chen G; Svirskis D; Wen J
J Pharm Pharmacol; 2015 Nov; 67(11):1528-36. PubMed ID: 26369422
[TBL] [Abstract][Full Text] [Related]
15. Long-circulatory nanoparticles for gemcitabine delivery: Development and investigation of pharmacokinetics and in-vivo anticancer efficacy.
Khare V; Singh A; Mahajan G; Alam N; Kour S; Gupta M; Kumar A; Singh G; Singh SK; Saxena AK; Mondhe DM; Gupta PN
Eur J Pharm Sci; 2016 Sep; 92():183-93. PubMed ID: 27404580
[TBL] [Abstract][Full Text] [Related]
16. 5-Fluorouracil encapsulated HA/PLGA composite microspheres for cancer therapy.
Lin Y; Li Y; Ooi CP
J Mater Sci Mater Med; 2012 Oct; 23(10):2453-60. PubMed ID: 22843166
[TBL] [Abstract][Full Text] [Related]
17. Synergistic targeting/prodrug strategies for intravesical drug delivery--lectin-modified PLGA microparticles enhance cytotoxicity of stearoyl gemcitabine by contact-dependent transfer.
Neutsch L; Wirth EM; Spijker S; Pichl C; Kählig H; Gabor F; Wirth M
J Control Release; 2013 Jul; 169(1-2):62-72. PubMed ID: 23588390
[TBL] [Abstract][Full Text] [Related]
18. Intracellular drug delivery using polysorbate 80-modified poly(D,L-lactide-co-glycolide) nanospheres to glioblastoma cells.
Tahara K; Kato Y; Yamamoto H; Kreuter J; Kawashima Y
J Microencapsul; 2011; 28(1):29-36. PubMed ID: 21171814
[TBL] [Abstract][Full Text] [Related]
19. Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro.
Li JM; Chen W; Wang H; Jin C; Yu XJ; Lu WY; Cui L; Fu DL; Ni QX; Hou HM
Acta Pharmacol Sin; 2009 Sep; 30(9):1337-43. PubMed ID: 19730429
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of gemcitabine and simvastatin through PLGA polymeric nanoparticles for the treatment of pancreatic cancer: in-vitro characterization, cellular uptake, and pharmacokinetic studies.
Jamil A; Aamir Mirza M; Anwer MK; Thakur PS; Alshahrani SM; Alshetaili AS; Telegaonkar S; Panda AK; Iqbal Z
Drug Dev Ind Pharm; 2019 May; 45(5):745-753. PubMed ID: 30632800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
